Catalyst Brief

← Calendar

Readoutin 104d

Aragon Pharmaceuticals, Inc. — Apalutamide

Phase 3 primary completion: An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS.

Date
Mar 2027
Type
Readout
Indication
Prostatic Neoplasms

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.